Asia-Pacific Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others) –Industry analysis, size, share, growth, trends, and forecasts (2016-2021).
- Advertising -
According to the report Asia Pacific Generic drugs market, published by Market Data Forecast, The Market was worth USD 38.04 Billion in 2015 and estimated to reach USD 67.04 Billion by 2021 with a growth potential of 12.0 %.
Browse market data tables and in-depth TOC of the Asia Pacific Generic drugs to 2021 at www.marketdataforecast.com/market-reports/asia-pacific-generic-drugs-market-2186/
Generic drugs are copies of branded drugs which have an exactly same composition, intended use, effects, side effects, risks, safety, and strength as the genuine drug. An example of a generic drug for diabetes is metformin.
They are cost effective compared to branded drugs.
- Advertising -
Generic drugs are also known as abbreviated drugs. To sell a generic drug manufacturing company must submit an Abbreviated New Drug Application for approval.
The Drug Price Competition and Patent Term Restoration Act of 1984, mostly known as the Hatch-Waxman Act, made ANDAs feasible by creating a compromise in the drug industry. Generic drug companies have obtained greater access to the market for prescription drugs and branded companies have obtained restoration of patent life for their drugs lost during FDA's approval process.
The cost-effectiveness of abbreviated drugs has given it a competitive lead over branded drugs in the market. Key driving factor for generic drugs is patent expiry for branded drugs.
Patent for Branded drugs with sales of up to USD 135 billion was expired in 2015. Nearly USD 150 Billion worth of patents for branded drugs will expire by 2020 which will give generic drugs a huge advantage.
One more trend which influences market growth is outsourcing. The presence of some key players in this market and developing economies are some driving factors in this region.
Vendors are using outsourcing as a strategy to reduce their capital which will be an advantage to generic drugs. Only restraint for this market is rigid rules setup by FDA for approval of these drugs and the threat of counterfeit drugs.
Asia Pacific Generic Drugs Market: Segmentation
- simple generics
- Super generics
- Y-o-Y Growth Analysis, By Product
- Market Attractiveness Analysis, By Product
- Market Share Analysis, By Product
- Therapeutic drugs
- Cardiovascular Products
- Anti-infective Drugs
- Anti Arthritis Drugs
- Central Nervous System Drugs
- Anti Cancer Drugs
- Respiratory System Drugs
- Y-o-Y Growth Analysis, By Therapeutic Drugs
- Market Attractiveness Analysis, By Therapeutic Drugs
- Market Share Analysis, By Therapeutic Drugs
- Geographical Analysis
- Asia Pacific
Reasons to access Asia Pacific Generic Drugs Market Report:
- Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
- Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
- Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
- Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economic, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
- Study the micro environmental factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
- A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
- Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
- An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
- Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Key players in this market are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...
For more information: